MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Ribonucleases as novel chemotherapeutics: the ranpirnase example

BioDrugs. 2008;22(1):53-8. [Link]

Lee JE, Raines RT.

Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USADivision of Biology, California Institute of Technology, Pasadena, California, USA.

Abstract

Ranpirnase, a cytotoxic ribonuclease from the frog Rana pipiens, is the archetype of a novel class of cancer chemotherapeutic agents based on homologs and variants of bovine pancreatic ribonuclease (RNase A). Ranpirnase in combination with doxorubicin is in clinical trials for the treatment of unresectable malignant mesothelioma and other cancers. The putative mechanism for ranpirnase-mediated cytotoxicity involves binding to anionic components of the extracellular membrane, cytosolic internalization, and degradation of transfer RNA leading to apoptosis. The maintenance of ribonucleolytic activity in the presence of the cytosolic ribonuclease inhibitor protein is a key aspect of the cytotoxic activity of ranpirnase. The basis for its specific toxicity for cancer cells is not known. This review describes the development of ranpirnase as a cancer chemotherapeutic agent.

Both comments and trackbacks are currently closed.